iPS Cells & Regenerative Medicine– category –
-
MIT and Johns Hopkins Develop 3D-Printed Handheld Microfluidic Device: Selectively Harvests Live Cells from Tissue for Early Cancer Detection and Personalized Therapy
3D Printing Industry USA Overview Researchers at MIT and Johns Hopkins University have developed a 3D-printed microfluidic handheld device capable of gently and selectively collecting live cells from freshly resected human tissue, while ... -
GC Cell’s CD5 CAR-NK Candidate ‘GCC2005’ Achieves 62.5% ORR in Phase 1a for NK/T-Cell Lymphoma, Demonstrating Long-Term Remission and Favorable Safety
더바이오 (The Bio) South Korea Overview GC Cell announced interim Phase 1a clinical trial results for its CD5-targeting allogeneic CAR-NK therapy candidate, GCC2005, at ICBMT 2026, achieving a 62.5% objective response rate (ORR) in 8 pat... -
Functional 3D Bioprinted Kidney Organoids Demonstrate Metabolic Filtration, Advancing Organ Transplant Alternatives
Zuglu Education USA Overview Researchers have successfully 3D bioprinted functional kidney organoids using iPS cells, angiogenic bio-inks, and laser-assisted bioprinting. These organoids were shown to filter metabolic waste and reabsorb ... -
iPS Cells & Regenerative Medicine Weekly Report September 26, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 26, 2026 (PDF) — Download Weekly Report September 26, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
Boehringer Ingelheim: $1B AI RNA splicing oncology roadmap with Envisagenics
AllSci USA Overview Envisagenics has partnered with Boehringer Ingelheim in a research and option agreement valued at over $1 billion for RNA splicing-targeted oncology therapeutics. Envisagenics will leverage its AI-driven SpliceCore pl... -
Sasineprocel: Aspen Neuroscience Parkinson’s therapy data for 2026
Aspen Neuroscience Unknown Overview Aspen Neuroscience announced the publication of preclinical data for Sasineprocel, its investigational autologous iPSC-derived cell therapy for Parkinson's disease, in the prestigious journal Cell Stem... -
CAR T-cells: Alpha-2,3-Sialylation function explained via BioRxiv
bioRxiv Unknown Overview A new preprint on bioRxiv, titled "CAR T-cells and is induced by LIF and glucocorticoids," suggests that α2,3-sialylation plays a role in CAR T-cell functional modulation, with induction by LIF and glucocorticoid... -
Fayuvi: FDA approval and specs for MPS IIIA gene therapy in 2026
CGTlive® USA Overview The FDA has granted approval to rebisufligene etisparvovec-hopf (Fayuvi), the first gene therapy for pediatric Sanfilippo Syndrome Type A (MPS IIIA). Fayuvi is a one-time intravenous AAV9 gene therapy designed to de... -
Evotec: iPSC-derived CAR γδ T-cell manufacturing specs for 2026
News-Medical.Net Germany Overview Evotec has established a scalable, xeno-free bioprocess platform for developing immune-evasive and tumor microenvironment (TME)-resistant iPSC-derived CAR γδ T-cells (CAR iγδ T-cells) targeting hepatocel... -
Anito-cel: Phase 1 trial specs and 100% response rate for CAR-T
EurekAlert! (via Mass General Brigham) USA Overview In a Phase 1 clinical trial led by Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center, the BCMA-targeted CAR-T cell therapy, anitoc...
